The verdict in U.S. District Court in Brooklyn came on the fifth day of deliberations, which followed a monthlong trial.
After five days of deliberations, a federal jury in NY on Friday found Shkreli guilty on three of eight charges, two counts of securities fraud, and one count of conspiracy to commit securities fraud.
He faces up to 20 years in prison when he is sentenced.
Shkreli became a lightning rod in 2015 when Turing bought the rights to sell Daraprim, a drug available since 1953 to treat a parasite infection, to $750 a pill. Prosecutors said that Shkreli arranged to pay the defrauded MSMB investors "by creating fake agreements making it look like the investors were consulting for Retrophin, or signing settlement agreements requiring Retrophin to pay the investors, when Retrophin had no such responsibility".
Shutdown, restrictions hit Indian-controlled Kashmir following death of civilian
The state government has closed all the colleges and schools in wake of the students protests. A fierce gunfight followed, police sources said.
The charges are related to Shkreli's operation of a pair of hedge funds, MSMB Capital and MSMB Healthcare. His defense team argued that his investors made hefty profits.
Prosecutors had accused Shkreli of repeatedly misleading investors about what he was doing with their money.
"Who lost anything? Nobody", defense attorney Ben Brafman said in his closing argument.
After almost a week of deliberations, a jury found Shkreli guilty of three of eight counts of securities and wire fraud.
"The SEC's complaint alleges "widespread fraudulent conduct" by Shkreli - a series of misrepresentations and omissions, and of taking money from one fund to cover claims against the other".